Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228039 | 0.85 | GSR (0.50) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL382017 | 0.83 | GSR (0.48) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL24075891 | 0.83 | GSR (0.48) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL14890176 | 0.83 | GSR (0.48) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL158632 | 0.83 | GSR (0.48) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL30037850 | 0.82 | FOLH1 (0.49) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL388186 | 0.81 | GSR (0.47) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL6267879 | 0.81 | GSR (0.47) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| Water SCHEMBL1007984 | 0.81 | GSR (0.47) | GSRRNPEPCPB2FOLH1CYP2D6 | |
| SCHEMBL6028111 | 0.81 | GSR (0.47) | GSRRNPEPCPB2FOLH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431527-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | THE INSTITUTE FOR CANCER RESEARCH | 2011-02-10 | — | — | US | disclosed |
| WO-2000024405-A9 | COMPOUNDS AND THEIR THERAPEUTIC USE WITH DIABETIC COMPLICATIONS | FOX CHASE CANCER CENTER (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034522-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | AGER, ALDOA, FBP1 | GSR 295/4885RNPEP 1418/4885CPB2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.